BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16757611)

  • 21. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
    Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products.
    Geraets DT; Heideman DA; de Koning MN; Snijders PJ; Meijer CJ; van Doorn LJ; Quint WG
    J Clin Virol; 2009 Nov; 46 Suppl 3():S16-20. PubMed ID: 20129069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens.
    Kapala J; Jang D; Patel J; Biers K; Smieja M; Chernesky M
    J Virol Methods; 2007 Jun; 142(1-2):223-5. PubMed ID: 17320978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.
    Tao K; Yang J; Yang H; Guo ZH; Hu YM; Tan ZY; Zhang F; Duan JL
    Diagn Cytopathol; 2014 Mar; 42(3):213-7. PubMed ID: 23904341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.
    Monsonego J; Pintos J; Semaille C; Beumont M; Dachez R; Zerat L; Bianchi A; Franco E
    Int J Gynecol Cancer; 2006; 16(2):591-8. PubMed ID: 16681731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
    Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Doutre S; Michelow P; Kelly H; Didelot MN; Chikandiwa A; Sawadogo B; Delany-Moretlwe S; Meda N; Costes V; Mayaud P; Segondy M
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):162-8. PubMed ID: 25394189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear.
    Monsonego J; Pollini G; Evrard MJ; Sednaoui P; Monfort L; Quinzat D; Dachez R; Syrjänen K
    Int J STD AIDS; 2008 Jun; 19(6):385-92. PubMed ID: 18595876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.
    Bottari F; Iacobone AD; Radice D; Preti EP; Preti M; Franchi D; Piana AF; Sandri MT; Passerini R
    J Med Virol; 2021 Nov; 93(11):6340-6346. PubMed ID: 33565607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness.
    Kaufman RH; Adam E; Icenogle J; Reeves WC
    Am J Obstet Gynecol; 1997 Oct; 177(4):930-6. PubMed ID: 9369847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology.
    Geraets DT; Heideman DA; de Koning MN; Snijders PJ; van Alewijk DC; Meijer CJ; van Doorn LJ; Quint WG
    J Clin Virol; 2009 Nov; 46 Suppl 3():S21-6. PubMed ID: 20129070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples.
    Poljak M; Fujs K; Seme K; Kocjan BJ; Vrtacnik-Bokal E
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Dec; 14(4):147-52. PubMed ID: 16435043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of PapType to Digene Hybrid Capture 2, Roche linear array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal pap smears.
    Tabrizi SN; Stevens MP; Khan ZA; Chow C; Devitt MA; Garland SM
    J Clin Microbiol; 2012 Aug; 50(8):2796-8. PubMed ID: 22649012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
    Chung HS; Hahm C; Lee M
    J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.
    Recio FO; Sahai Srivastava BI; Wong C; Hempling RE; Eltabbakh GH; Piver MS
    Eur J Gynaecol Oncol; 1998; 19(3):203-8. PubMed ID: 9641214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia.
    Phillips S; Garland SM; Tan JH; Quinn MA; Tabrizi SN
    J Clin Virol; 2015 Jan; 62():63-5. PubMed ID: 25542473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the clinical performance of restriction fragment mass polymorphism (RFMP) and Roche linear array HPV test assays for HPV detection and genotyping.
    Lee HP; Cho W; Bae JM; Shin JY; Shin SK; Hwang SY; Min KT; Kim SN; Lee SJ; Kim SO; Yoo WD; Hong SP
    J Clin Virol; 2013 Jun; 57(2):130-5. PubMed ID: 23410688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of human papillomavirus in intraepithelial lesions and carcinoma of the cervix uteri in southern Thai women.
    Tungsinmunkong K; Suwiwat S; Sriplung H
    Asian Pac J Cancer Prev; 2006; 7(3):427-30. PubMed ID: 17059337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.
    Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J
    J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.